Skip to main content
. 2013 Jun;57(6):2809–2814. doi: 10.1128/AAC.02513-12

Fig 2.

Fig 2

Dose fractionation study results for the low- (A), medium- (B) and high-level (C) CTX-M-15-producing E. coli. The effect of each active regimen is shown relative to the no-treatment controls. CXA-101, ceftolozane; Tazo, tazobactam; Q8h, every 8 h.